Home FDA Approves Expanded Indication for Mercks KEYTRUDA (pembrolizumab) for the Treatment of Patients with Advanced Melanoma
 

Keywords :   


FDA Approves Expanded Indication for Mercks KEYTRUDA (pembrolizumab) for the Treatment of Patients with Advanced Melanoma

2015-12-18 22:05:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. KEYTRUDA is Now the First and Only Anti-PD-1 Therapy to Achieve Superior Overall Survival Compared to Ipilimumab KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for KEYTRUDA (pembrolizumab), the companys anti-PD-1 (programmed death receptor-1) therapy, to include the first-line treatment of patients with unresectable or metastatic melanoma. Language: English Contact: MerckMedia Contacts:Pamela Eisele, 267-305-3558orAn Phan, 908-255-6325orInvestor Contacts:Teri Loxam, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: with advanced treatment expanded

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Forecast Discussion Number 6
05.11Tropical Storm Rafael Wind Speed Probabilities Number 6
05.11Tropical Storm Rafael Public Advisory Number 6
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Tropical Storm Rafael Forecast Advisory Number 6
05.11Why colouring clothes has a big environmental impact
05.11Atlantic Tropical Weather Outlook
More »